A patient stabilized on oral aripiprazole wants a long-acting injectable before discharge. He tolerated oral therapy for 2 weeks, has no CYP2D6 inhibitor, and cannot return for weekly visits. Which implementation detail is critical for aripiprazole monohydrate LAI?
